These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 23458532)

  • 1. Letter: should immunosuppressive therapy be started with adalimumab in Crohn's disease?
    Tursi A
    Aliment Pharmacol Ther; 2013 Apr; 37(7):752. PubMed ID: 23458532
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter: should immunosuppressive therapy be started with adalimumab in Crohn's disease? Authors' reply.
    Reenaers C; Louis E; Belaiche J; Seidel L; Keshav S; Travis S
    Aliment Pharmacol Ther; 2013 Apr; 37(7):752-3. PubMed ID: 23458531
    [No Abstract]   [Full Text] [Related]  

  • 3. [Adalimumab vasculitis in a patient with Crohn's disease].
    Muñoz Villafranca C; Izu Belloso RM; Bravo Rodriguez MT; Basterra Olabarrieta S
    Gastroenterol Hepatol; 2013 Apr; 36(4):296-7. PubMed ID: 23522950
    [No Abstract]   [Full Text] [Related]  

  • 4. Commentary: IBD combination therapy - adalimumab plus immunosuppressants.
    Andrews JM
    Aliment Pharmacol Ther; 2013 Jan; 37(1):156. PubMed ID: 23205476
    [No Abstract]   [Full Text] [Related]  

  • 5. Adalimumab reversed a severe lymphopenia in a patient with Crohn's disease.
    Taxonera C; Mendoza JL; Ortega L; Pérez MI; Díaz-Rubio M
    J Crohns Colitis; 2012 May; 6(4):488-91. PubMed ID: 22398051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Letter: infliximab and adalimumab in the management of Crohn's disease--are they really comparable?
    Lopez-Sanroman A; Gisbert JP
    Aliment Pharmacol Ther; 2012 Sep; 36(5):498-9. PubMed ID: 22860615
    [No Abstract]   [Full Text] [Related]  

  • 7. Letter: are infliximab and adalimumab similar for Crohn's disease in clinical practice?
    Tursi A; Elisei W; Picchio M; Penna A
    Aliment Pharmacol Ther; 2013 Apr; 37(7):763-4. PubMed ID: 23458543
    [No Abstract]   [Full Text] [Related]  

  • 8. Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.
    Absah I; Faubion WA
    Inflamm Bowel Dis; 2012 Aug; 18(8):1488-92. PubMed ID: 21882301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological therapy for Crohn's disease in a liver transplant patient.
    Bendezú García RA; Rodríguez Manrique MA; Hernández Martínez A; Lázaro Sáez M; Patrón Román GO; Amat Alcaraz S; Vega Sáenz JL
    J Dig Dis; 2013 Oct; 14(10):564-6. PubMed ID: 23437819
    [No Abstract]   [Full Text] [Related]  

  • 10. Successful treatment with adalimumab in infliximab-resistant Crohn's disease.
    Barthel HR; Gille T; Halbsguth A; Kramer M
    J Gastroenterol Hepatol; 2005 Sep; 20(9):1464-5. PubMed ID: 16105142
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinically silent Crohn's disease in a patient with Takayasu's arteritis unresponsive to conventional therapies.
    Yilmaz N; Can M; Alibaz-Oner F; Direskeneli H
    Rheumatol Int; 2013 Dec; 33(12):3091-3. PubMed ID: 23143554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Commentary: infliximab or adalimumab in Crohn's disease?
    Sprakes MB; Hamlin PJ
    Aliment Pharmacol Ther; 2012 Aug; 36(4):398. PubMed ID: 22803644
    [No Abstract]   [Full Text] [Related]  

  • 13. Sarcoidosis complicating treatment with adalimumab for Crohn's disease.
    McDonnell MJ; Rutherford RM; O'Regan A
    J Crohns Colitis; 2014 Sep; 8(9):1140-1. PubMed ID: 24631310
    [No Abstract]   [Full Text] [Related]  

  • 14. Acute coronary syndrome in a Crohn's disease patient treated with adalimumab.
    Petitpain N; Bornert-Keller N; Peyrin-Biroulet L
    J Crohns Colitis; 2013 Oct; 7(9):e396. PubMed ID: 23523265
    [No Abstract]   [Full Text] [Related]  

  • 15. Listeria monocytogenes infection in Crohn's disease treated with adalimumab.
    Willson KJ; Jacob A; Shetti MP; Bhatia R; Yee K; Osler W
    Med J Aust; 2012 Oct; 197(8):466-7. PubMed ID: 23072245
    [No Abstract]   [Full Text] [Related]  

  • 16. [Efficacy and safety of Adalimumab in Crohn's disease].
    Serghini M; Haddad W; Jeddi H; Karoui S; Ben Mustapha N; Kallel L; Fekih M; Matri S; Boubaker J; Filali A
    Tunis Med; 2012 Feb; 90(2):101-7. PubMed ID: 22407620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary carcinoid tumor in a patient on adalimumab for Crohn's disease.
    Betteridge JD; Veerappan GR
    Inflamm Bowel Dis; 2013 Feb; 19(2):E29-30. PubMed ID: 22447376
    [No Abstract]   [Full Text] [Related]  

  • 18. Anti-tumor necrosis factor agents reduce corticosteroid use compared with azathioprine in patients with Crohn's disease.
    Kane SV; Jaganathan S; Bedenbaugh AV; Palmer L; Schwartz DA
    Curr Med Res Opin; 2014 Sep; 30(9):1821-6. PubMed ID: 24884302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adalimumab in Crohn's disease patients: pharmacokinetics in the first 6 months of treatment.
    Lie MR; Peppelenbosch MP; West RL; Zelinkova Z; van der Woude CJ
    Aliment Pharmacol Ther; 2014 Nov; 40(10):1202-8. PubMed ID: 25263077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple and fulminant cutaneous squamous cell carcinomas in a Crohn's disease patient treated with immunosuppressants and adalimumab.
    Nancey S; Boschetti G; Cotte E; Cathey-Javouhay A; Laidet M; Chichery A; Francois Y; Glehen O; Flourié B
    Inflamm Bowel Dis; 2011 Apr; 17(4):1060-1. PubMed ID: 21391289
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.